[
  {
    "ts": null,
    "headline": "Adimab Reports Strong Partnering Year for 2025",
    "summary": "Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it entered into partnership agreements with 23 companies in 2025. In addition, Adimab achieved 50 technical and development milestones across numerous collaborations.",
    "url": "https://finnhub.io/api/news?id=0ea5b719e7392abac7aa1fdfe58b8bfdc207fca01ab520e4e7c8d919405bb0a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768247820,
      "headline": "Adimab Reports Strong Partnering Year for 2025",
      "id": 138078029,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it entered into partnership agreements with 23 companies in 2025. In addition, Adimab achieved 50 technical and development milestones across numerous collaborations.",
      "url": "https://finnhub.io/api/news?id=0ea5b719e7392abac7aa1fdfe58b8bfdc207fca01ab520e4e7c8d919405bb0a0"
    }
  },
  {
    "ts": null,
    "headline": "FPX: Leading IPO ETF With A Few Unexpected Holdings",
    "summary": "FPX holds 101 IPO and spin-off stocks in 1,000 days, across tech, industrials, healthcare, strong returns, 14% seasoned via M&A. Read why FPX ETF is a hold.",
    "url": "https://finnhub.io/api/news?id=b27e0a6b1a91325bca2c086dae18f6ba229f776a91d9f17191e0d0ec2c397e58",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768184164,
      "headline": "FPX: Leading IPO ETF With A Few Unexpected Holdings",
      "id": 138068572,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2207303700/image_2207303700.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "FPX holds 101 IPO and spin-off stocks in 1,000 days, across tech, industrials, healthcare, strong returns, 14% seasoned via M&A. Read why FPX ETF is a hold.",
      "url": "https://finnhub.io/api/news?id=b27e0a6b1a91325bca2c086dae18f6ba229f776a91d9f17191e0d0ec2c397e58"
    }
  },
  {
    "ts": null,
    "headline": "A big Wall Street flip just changed the Regeneron narrative",
    "summary": "Bank of America Global Research upped its rating on Regeneron Pharmaceuticals and its price target to $860 because it has a better view on Eylea HD, Dupixent is growing steadily, and there are several catalysts for 2026. Bank of America Global Research raised its rating on Regeneron ...",
    "url": "https://finnhub.io/api/news?id=beab187b4ccfad430be22b4edc548a86958427463f04b4e58e3da37e069f792b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768181492,
      "headline": "A big Wall Street flip just changed the Regeneron narrative",
      "id": 138069196,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Bank of America Global Research upped its rating on Regeneron Pharmaceuticals and its price target to $860 because it has a better view on Eylea HD, Dupixent is growing steadily, and there are several catalysts for 2026. Bank of America Global Research raised its rating on Regeneron ...",
      "url": "https://finnhub.io/api/news?id=beab187b4ccfad430be22b4edc548a86958427463f04b4e58e3da37e069f792b"
    }
  }
]